European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Mechanisms of functionalized nanomaterials binding to microbes in gut

Descrizione del progetto

Nanomateriali per eliminare gli agenti patogeni

Il trattamento antibiotico, necessario per uccidere gli agenti patogeni, colpisce al tempo stesso l’omeostasi del microbioma, causando la deregolamentazione immunitaria. Gli scienziati del progetto NanoBindMicro, finanziato dall’UE, propongono un diverso approccio contro gli agenti patogeni basato sulle nanotecnologie. La logica è quella di utilizzare nanomateriali funzionalizzati per riconoscere ed eliminare specifici agenti patogeni dai 100 trilioni di microbi presenti nell’intestino. Le specifiche molecole superficiali degli agenti patogeni agiranno da ligandi mirati per questi nanomateriali funzionalizzati al fine di superare i siti di legame degli agenti patogeni sull’epitelio. I risultati del progetto dispongono del potenziale per contribuire a un nuovo approccio senza antibiotici finalizzato ad affrontare gli agenti patogeni multifarmacoresistenti e a ridurre la necessità pressante di scoprire nuovi antibiotici.

Obiettivo

Antibiotic-resistant microbes have become a serious health problem world-wide. Development of new antibiotics has been focused on killing pathogens. However, these antibiotics also kill other components of microbiome resulting in immune dysregulation. It is crucial to develop new strategies which can remove pathogens without damaging the homeostasis of the microbiome.

Nanotechnology is one of the key enabling technologies identified in the European Union (EU) 2020 Strategy that may be promising in dealing with antibiotic-resistant microbe. My recent study showed that microbes' binding to nanomaterials (NMs) was dependent on NMs' characteristics. This finding inspired me to consider whether I can find functionalized NMs to recognize and remove specific pathogens from 100 trillion microbes in gut and pose no harm to the other microbes. The idea is novel and does not follow the conventional use of NMs killing microbes directly, but I believe this is possible because microbes have very different cell surfaces. This would enable the design of NMs that bind certain microbes but not others.

I hypothesize that specific surface molecules of pathogens can be acted as the multiple targeted ligands for functionalized NMs to outcompete the binding sites of pathogens on the epithelium. To verify the hypothesis, I plan to use multiple ligand coated NMs, a new concept of personalized protein corona, and in vitro and in vivo gut microbiome models to study the mechanisms of functionalized nanomaterials binding to microbes in gut. My research experiences on nano-bio interactions combined with my host and collaborators’ expertise in nano-therapy (France), nano-protein corona (Germany) and nano-characterization (Denmark) will allow me to successfully execute this challenging program. The proposed study will result in a new strategy for using NMs to fight multi-resistant microbes without antibiotics.

Coordinatore

UNIVERSITE PARIS CITE
Contribution nette de l'UE
€ 196 707,84
Indirizzo
85 BD SAINT GERMAIN
75006 Paris
Francia

Mostra sulla mappa

Regione
Ile-de-France Ile-de-France Paris
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 196 707,84